Comparing the current results to its competitors, Marker Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 43.12 %, recorded in the same quarter.
Marker Therapeutics Inc 's Comment on Competition and Industry Peers
The company competes with various firms developing immunotherapies for cancer, including non-CD19 targeting CAR-T cells, multi-targeted CAR-T cells, NK-CAR therapies, and bispecific antibodies for lymphoma. Its product MT-601 is identified as the only natural T cell therapy targeting multiple tumor antigens for CAR relapse lymphoma patients. Competitors generally have greater resources and experience in drug discovery, development, clinical trials, regulatory approvals, manufacturing, marketing, and sales. Competition also arises from established therapies with proven safety and efficacy, alternative drug development technologies, new small molecules, and other therapeutic classes. Additionally, the company competes for collaborations, academic partnerships, and licensing agreements with pharmaceutical and biotechnology companies. Success depends on developing proprietary, superior, or lower-cost products and retaining key personnel.
December 19, 2024
In the realm of oncology, breakthroughs in treatment options can significantly alter the landscape of patient care and outcomes. A recent clinical update from Marker Therapeutics Inc. highlights encouraging developments in the treatment of lymphoma, particularly through their investigational therapy, MT-601. Situated within the ongoing APOLLO study, a significant share of patients have exhibited encouraging responses to this next-generation therapy.The APOLLO study, which focuses on patients with relapsed lymphoma, has reported striking results: an response rate of 78%, with a remarkable 44.4% of participants achieving a complete response (CR). These statistics underscore the potential of MT-601 as a transf...
April 8, 2024
The 11th Global Summit on Hematologic Malignancies held in Whistler, BC, Canada, served as a platform for leading experts in the field to discuss and share the latest advancements in the treatment of blood cancers. Among the distinguished speakers was a principal investigator from the prestigious City of Hope National Medical Center, who presented groundbreaking clinical data from the Marker Therapeutics APOLLO study. This article summarizes the key findings and implications of the study presented at the summit.Study Overview:The APOLLO study, conducted at the City of Hope National Medical Center, aimed to evaluate the efficacy and safety of a novel therapeutic approach developed by Marker Therapeutics for t...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Marker Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Marker Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
